ArticleCancer science2018
Correlation between CXCR4/CXCR7/CXCL12 chemokine axis expression and prognosis in lymph-node-positive lung cancer patients.
Article in Cancer science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- The clinicopathological and prognostic value of CXCR4 expression in patients with lung cancer: a meta-analysis.BMC cancer · 2022Pooled it
- CXCR4/CXCR7 gene-silencing suppresses ovarian cancer cell proliferation and tumour growth through modulation of the CXCL12-CXCR4/CXCR7 chemokine axis and activation of MAPK signalling pathway.Archives of medical science : AMS · 2026Article
- Chemokine Receptors in Peripheral Blood Mononuclear Cells as Predictive Biomarkers for Immunotherapy Efficacy in Non-Small Cell Lung Cancer.Current oncology (Toronto, Ont.) · 2025Review
- The novel functions of chemokines in lung cancer progression.Frontiers in immunology · 2025Review
- Cancer and Secretomes: HLA-G and Cancer Puzzle.Advances in experimental medicine and biology · 2025Review
- Prognostic Value of CXCL12 in Non-Small Cell Lung Cancer Patients Undergoing Tumor Resection.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Analysis of the chemotactic factors for tumor-infiltrating fibrocytes and their prognostic significances in lung cancer.Oncology letters · 2022Article
- CXC Chemokine Signaling in Progression of Epithelial Ovarian Cancer: Theranostic Perspectives.International journal of molecular sciences · 2022Review
- Genetic determinants of blood-cell traits influence susceptibility to childhood acute lymphoblastic leukemia.American journal of human genetics · 2021Article
- The CXCL12/CXCR7 signalling axis promotes proliferation and metastasis in cervical cancer.Medical oncology (Northwood, London, England) · 2021Article
- Article
- CXCL12 Signaling in the Tumor Microenvironment.Advances in experimental medicine and biology · 2021Review
- Predictive and Prognostic Biomarkers for Lung Cancer Bone Metastasis and Their Therapeutic Value.Frontiers in oncology · 2021Review
- Construction of a Ferroptosis-Related Long Non-coding RNA Prognostic Signature and Competing Endogenous RNA Network in Lung Adenocarcinoma.Frontiers in cell and developmental biology · 2021Article
- Deletion of Wild-type p53 Facilitates Bone Metastatic Function by Blocking the AIP4 Mediated Ligand-Induced Degradation of CXCR4.Frontiers in pharmacology · 2021Article
- Overexpression of CXCR7 accelerates tumor growth and metastasis of lung cancer cells.Respiratory research · 2020Article
- EEF1A2 and ERN2 could potentially discriminate metastatic status of mediastinal lymph node in lung adenocarcinomas harboring EGFR 19Del/L858R mutations.Thoracic cancer · 2020Article
- KRT8 and KRT19, associated with EMT, are hypomethylated and overexpressed in lung adenocarcinoma and link to unfavorable prognosis.Bioscience reports · 2020Article
- Targeting pulmonary tumor microenvironment with CXCR4-inhibiting nanocomplex to enhance anti-PD-L1 immunotherapy.Science advances · 2020Article
- In silico analysis of the immune microenvironment in bladder cancer.BMC cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The CXCR4/CXCR7/CXCL12 chemokine axis plays important roles in the migration of tumor cells during cancer development by modulating site-specific distant metastasis including to regional lymph nodes. We investigated the correlation of these chemokine expressions to prognosis in lymph-node-positive non-small-cell lung cancer (NSCLC) patients. A total of 140 surgically resected specimens of primary site (PS) and metastatic lymph nodes (MLN) of NSCLC involving hilar and/or mediastinal lymph nodes (N1-2) were collected. CXCR4, CXCR7 and CXCL12 expressions were evaluated. Cox regression analysis was performed to determine whether these chemokines were independent prognostic factors in N1-2 NSCLC. High expression of CXCR4 in PS and CXCL12 in MLN was associated with poor overall survival (OS) (P = .025 and .033, respectively). Significant correlations between CXCR4 expression in PS and CXCL12 expression in MLN were observed (P = .040). There was significant difference in OS between 2 groups according to expressions of CXCR4 in PS and CXCL12 in MLN (P = .0033). Expression of CXCL12 in MLN was identified as an independent prognostic factor (HR 1.79, 95% CI 1.08-3.04, P = .023). CXCL12 in MLN was mainly expressed by tumor cells compared with stromal cells (56% vs 25%, respectively, P < .0001). CXCR4/CXCL12 may play roles in tumor progression in MLN and is associated with poor prognosis of lymph-node-positive NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.